Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors

BRAF and MEK inhibitors (BRAFi and MEKi) are the standard of care for the treatment of metastatic melanoma in patients with BRAF(V600E) mutations, greatly improving progression-free survival. However, the acquisition of resistance to BRAFi and MEKi remains a difficult clinical challenge, with limite...

Descripción completa

Detalles Bibliográficos
Autores principales: Leclair, Héloïse M., Tardif, Nina, Paris, Anaïs, Galibert, Marie-Dominique, Corre, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404066/
https://www.ncbi.nlm.nih.gov/pubmed/32708687
http://dx.doi.org/10.3390/ijms21145025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404066/
https://www.ncbi.nlm.nih.gov/pubmed/32708687
http://dx.doi.org/10.3390/ijms21145025

Ejemplares similares